drugset / Trial / NCT04817917

Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province

NCT04817917

Non-randomizedParallel-groupOpen-labelPrevention

Summary

This study is to evaluate the seroprevalence of neutralizing antibodies against Japanese encephalitis (JE) virus in children aged 6 years who were previously administered with 5 different immunization strategies by JE attenuated live vaccine (JEV-L) or/and inactivated vaccine (JEV-I). The secondary objective is to evaluate the immunogenicity of the booster dose of JEV-I at 6 years old for those previously immunized with 3 doses of JEV-I or those sequential administered with 1 dose of JEV-L and another dose of JEV-I.

Timeline

Start
2021-03-01
Primary completion
2022-09-17
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Japanese Encephalitis Vaccine (Vero Cell), Inactivated Vaccine

Indications